Navigation Links
WuXi Manufacturing Facility Passes FDA Inspection
Date:10/29/2013

SHANGHAI, Oct. 29, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that the small molecule API and advanced intermediate manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration with no Form 483 issued.

STA has built a substantial manufacturing pipeline of small molecule APIs and advanced intermediates for our global clients through its integrated platform, which extends from process research and research manufacturing to commercial manufacturing.  This inspection outcome confirms STA's capabilities in helping the clients move their new chemical entities through clinical development stages and eventually to commercial launch in the global market.  

"The result of this inspection speaks to WuXi's high standards of quality," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  "We continue to leverage our knowledge and that of our partners to build and operate a first-class quality system in China that meets global regulatory requirements."

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech.  Please visit http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com  

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
pr@wuxiapptec.com  


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
3. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
4. Emerging Trends in Medical Device Outsourcing and Contract Manufacturing
5. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
6. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
7. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
8. Divine Skin To Begin Manufacturing Its OTC Pain Reliever
9. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
10. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
11. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/6/2017)... July 6, 2017 ThriveRx, the nutrition division of Diplomat Specialty ... to thrive on nutrition support. To celebrate its anniversary, ThriveRx ... has a fresh new look with improved organization to create the best ... ... "We,ve made ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is ... Schaumburg, IL, with or without a referral. Understanding the difficulties that face people who ... when they choose this permanent alternative to removable dentures and bridges. Not only does ...
(Date:7/20/2017)... , ... July 19, 2017 , ... ... $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral dental ... health care needs in rural and underserved areas. , The Predoctoral Pediatric Training ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... may sometimes lead to, or worsen, varicose veins in some patients, according to ... while avoiding certain not-so-good practices, like excessive sitting or standing, or regularly nicking ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... Calif. (PRWEB) , ... July 18, 2017 , ... The results of an international clinical ... a drug therapy for a severe type of muscular dystrophy holds promise for a subgroup ... , Craig McDonald and colleagues at 53 study sites in 18 countries describe ...
Breaking Medicine News(10 mins):